Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung
Extracellular Vesicle · 2022-12 · 1 · 100002
DOI: 10.1016/j.vesic.2022.100002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Extracellular Vesicle, 2022-12. Verfasst von Kristen D Popowski und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, NC, 27607, USA. Die Arbeit wurde bisher 150-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Respiratory diseases are among the leading causes of morbidity and mortality worldwide, coupled with the ongoing coronavirus disease 2019 (COVID-19) pandemic. mRNA lipid nanoparticle (LNP) vaccines have been developed, but their intramuscular delivery limits pulmonary bioavailability. Inhalation of nanoparticle therapeutics offers localized drug delivery that minimizes off targeted adverse effects and has greater patient compliance. However, LNP platforms require extensive reformulation for inhaled delivery. Lung-derived extracellular vesicles (Lung-Exo) offer a biological nanoparticle alternative that is naturally optimized for mRNA translation and delivery to pulmonary cells. We compared the biodistribution of Lung-Exo against commercially standard biological extracellular vesicles (HEK-Exo) and LNPs (Lipo), where Lung-Exo exhibited superior mRNA and protein cargo distribution to and retention in the bronchioles and parenchyma following nebulization administration. This suggests that inhaled Lung-Exo can deliver mRNA and protein drugs with enhanced pulmonary bioavailability and therapeutic efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, NC, 27607, USA.
- Comparative Medicine Institute, North Carolina State University, Raleigh, NC, 27607, USA.
- Department of Molecular and Structural Biochemistry, North Carolina State University, Raleigh, NC, 27695, USA.
- Department of Biological Sciences, North Carolina State University, Raleigh, NC, 27695, USA.
- Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh/Chapel Hill, NC, 27607/27599, USA.
- Department of Animal Sciences, North Carolina State University, Raleigh, NC, 27607, USA.
Förderung
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
- American Heart Association Inc
Zitieren
APA
Popowski, K. D., López de Juan Abad, B., George, A., Silkstone, D., Belcher, E., Chung, J., Ghodsi, A., Lutz, H., Davenport, J., Flanagan, M., Piedrahita, J., Dinh, P. C., & Cheng, K. (2022). Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung. Extracellular Vesicle, 1, 100002. https://doi.org/10.1016/j.vesic.2022.100002
Vancouver
Popowski KD, López de Juan Abad B, George A, Silkstone D, Belcher E, Chung J, et al. Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung. Extracellular Vesicle. 2022;1:100002. doi:10.1016/j.vesic.2022.100002
BibTeX
@article{Popowski2022,
author = {Popowski, Kristen D and López de Juan Abad, Blanca and George, Arianna and Silkstone, Dylan and Belcher, Elizabeth and Chung, Jaewook and Ghodsi, Asma and Lutz, Halle and Davenport, Jada and Flanagan, Mallory and Piedrahita, Jorge and Dinh, Phuong-Uyen C and Cheng, Ke},
title = {Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung},
journal = {Extracellular Vesicle},
year = {2022},
volume = {1},
pages = {100002},
doi = {10.1016/j.vesic.2022.100002}
}
EUVIMED